Visit : www.acriindia.com
ACRI is a leading pharmacovigilance training Institute in Bangalore.
ACRI creates a value add for every degree. Our PG course is diploma in clinical research and PG diploma in pharmavigilance are approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
Pharmacovigilanc: The science & activities relating to the Detection, Assessment, Understanding and Prevention of adverse effects or any other drug related problems
The Thalidomide Tragedy (Lessons for Drug Safety and Regulation)
CLASSIFICATION OF ADRS (RAWLIN AND THOMPSON CLASSIFICATION)
Why PV is Necessary?
Objective of PV
Outcomes of Drugs
Causal Relationship
Adverse drug reaction and causality assessment scales
Classification of AE
Serious Adverse Event (SAE)
Sources of Adverse Events (AE) reports
Sources of AE Reports(Solicited Reports)
What to Report?
Who to Report?
When to Report?
Individual case data flow
Pharmacovigilance and product quality assessmentpi
What are the different pharmacovigilance roles and responsibilities in a manufacturing environment? This presentation focuses on the relationship between pharmacovigilance and product quality assessement.
Pharmacovigilanc: The science & activities relating to the Detection, Assessment, Understanding and Prevention of adverse effects or any other drug related problems
The Thalidomide Tragedy (Lessons for Drug Safety and Regulation)
CLASSIFICATION OF ADRS (RAWLIN AND THOMPSON CLASSIFICATION)
Why PV is Necessary?
Objective of PV
Outcomes of Drugs
Causal Relationship
Adverse drug reaction and causality assessment scales
Classification of AE
Serious Adverse Event (SAE)
Sources of Adverse Events (AE) reports
Sources of AE Reports(Solicited Reports)
What to Report?
Who to Report?
When to Report?
Individual case data flow
Pharmacovigilance and product quality assessmentpi
What are the different pharmacovigilance roles and responsibilities in a manufacturing environment? This presentation focuses on the relationship between pharmacovigilance and product quality assessement.
Introduction to Aggregate Reporting in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
After adoption and success of E2B R2 for almost a decade finally change was brought to tear down and bring some more updates to the existing ICSR Elements Design.
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
MedDRA - the Medical Dictionary for Regulatory Activities - is a medical terminology used to classify adverse event information associated with the use of biopharmaceuticals and other medical products (e.g., medical devices and vaccines). Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyze data related to the safe use of medical products.
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
A brief description about Pharmacovigilance, aims and scope, need of pharmacovigilance, programs by WHO for international drug safety monitoring, UMC, VIGIBASE, WHO causality assessment scale and specific regulatory bodies of various countries
GVP stands for Good Pharmacovigilance Practices, which are a set of guidelines and regulatory requirements that provide a framework for the conduct of pharmacovigilance activities. The GVP modules outline specific areas of pharmacovigilance and provide detailed guidance on various aspects. Here are the main GVP modules
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
Introduction to ICSR Narrative Writing in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance is a scientific discipline concerned with the collection, detection, assessment, monitoring, and prevention of adverse effects of pharmaceutical products.
Pharmacovigilance is a branch of Pharmacoepidemiology and is restricted to the study of adverse effects of drugs.
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...Pristyn Research Solutions
Quick Job interview short guide For Pharma and all Life science jobseekers.All Medical | Biotech |Micro |B.Sc., M.Sc.
These are the commonly asked questions with their answers asked in job interviews. The file was updated in 2022.
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4, Opposite To Expert Global, Garware Stadium Road, Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 9028839789
Sample Questions are:
What is Pharmacovigilance (PV)?
What are the objectives of PV?
What is MedDRA?
WHAT ARE THE Role of Drug Safety
Associate?
What should narratives consist of?
What are Data assessments in PV?
Which products are covered by PV?
Methods of signal detection?
Why PV is required after clinical
trial?
What is an Adverse Drug Event (ADE)?
What
is the minimum criterion required
for a valid case according to WHO?
When
do you consider an event to be
serious?
What do you mean by causality?
Types of
Unsolicited reports
Sources of Solicited Reports
Name the core regulatory bodies
What is Volume 9A
What do you know
about E2a, E2b and E2c guidelines?
When do you consider a case to be medically confirmed?
What is CemFlow?
What is the yellow card in PV?
What are Comorbid conditions?
What is a medication error?
What is a signal?
Rechallenge
Dechallenge
What are WHO ART, WHO DD and MedDRA and the difference between them?
What is SUSAR?
Adverse Drug Reaction (ADR)
Effectiveness/risk
harm
Essential medicines
Frequency of ADRs
Individual Case Safety Report
ADR Reporting process in PV
VigiFlow
VigiMed
ABBOTTS
COGNIZANT
I 3 GLOBAL DRUG
SAFETY
LAURUS LABS
PARAXEL
SRISTEK
ACCENTURE
CREST.
I GATE PATNI
COMPUTERS
MAHINDRA
SATYAMBSG
PIRAMAL
SUN
PHARMA
ALEMBIC
DIAGNOSEAR
CH
ICON
MAKROCARE
PPD
SYMOGEN
APC PHARMA.
DR REDDY’S
iMEDGlobal,
MANKIND
QUANTUM
SOLUTIONS
SYNOGEN
APCER
ECRON
ACUNOVA
IMS HEALTH
MEDHIMALAYAS
QUINTILES
TAKE
SOLUTIONS
APCER
EMCURE
INC RESEARCH
MEDPACE.
SCIFORMIX
RATIOPHARM
TCS
ASTRAZENECA
FDC
Infocorp
Soft
Solutions
MICRO LABS
RX MD
THOMSON
REUTERS
AUROBINDO
FORTIS
HEALTH CARE
INVENTIVE
MSD (MERCK)
SANTHA
BIOTECH
USV
LIMITED
BESTOCHEM
G7 INFOTECH
IPCA
LABORATORIES
NEKTAR
THERAPEUTICS
SCIFORMIX.
VIMTA LABS
BIOCAD
GENPACT
IPLEX
NORWICH
CLINICAL SERVICES
SHANTHA
BIOTECHNICS
WIPRO
BIOCON
GRANULES
JUBILIANT
BIOSYS NOVARTIS
SIRO
CLINPHARM
WNS
BIOLOGICAL E.
LTD
GVK
KINAPSE
NOVO NORDISK
SP softtech
WOCKHARD
T
BLUEFISH
HCL
LAMBDA
OMNICARECLINICA
L RESEARCH
SRI KRISHNA
PHARMA
4C
Pharma
Solutions
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Aggregate Reporting in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
After adoption and success of E2B R2 for almost a decade finally change was brought to tear down and bring some more updates to the existing ICSR Elements Design.
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
MedDRA - the Medical Dictionary for Regulatory Activities - is a medical terminology used to classify adverse event information associated with the use of biopharmaceuticals and other medical products (e.g., medical devices and vaccines). Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyze data related to the safe use of medical products.
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
A brief description about Pharmacovigilance, aims and scope, need of pharmacovigilance, programs by WHO for international drug safety monitoring, UMC, VIGIBASE, WHO causality assessment scale and specific regulatory bodies of various countries
GVP stands for Good Pharmacovigilance Practices, which are a set of guidelines and regulatory requirements that provide a framework for the conduct of pharmacovigilance activities. The GVP modules outline specific areas of pharmacovigilance and provide detailed guidance on various aspects. Here are the main GVP modules
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
Introduction to ICSR Narrative Writing in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance is a scientific discipline concerned with the collection, detection, assessment, monitoring, and prevention of adverse effects of pharmaceutical products.
Pharmacovigilance is a branch of Pharmacoepidemiology and is restricted to the study of adverse effects of drugs.
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...Pristyn Research Solutions
Quick Job interview short guide For Pharma and all Life science jobseekers.All Medical | Biotech |Micro |B.Sc., M.Sc.
These are the commonly asked questions with their answers asked in job interviews. The file was updated in 2022.
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4, Opposite To Expert Global, Garware Stadium Road, Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 9028839789
Sample Questions are:
What is Pharmacovigilance (PV)?
What are the objectives of PV?
What is MedDRA?
WHAT ARE THE Role of Drug Safety
Associate?
What should narratives consist of?
What are Data assessments in PV?
Which products are covered by PV?
Methods of signal detection?
Why PV is required after clinical
trial?
What is an Adverse Drug Event (ADE)?
What
is the minimum criterion required
for a valid case according to WHO?
When
do you consider an event to be
serious?
What do you mean by causality?
Types of
Unsolicited reports
Sources of Solicited Reports
Name the core regulatory bodies
What is Volume 9A
What do you know
about E2a, E2b and E2c guidelines?
When do you consider a case to be medically confirmed?
What is CemFlow?
What is the yellow card in PV?
What are Comorbid conditions?
What is a medication error?
What is a signal?
Rechallenge
Dechallenge
What are WHO ART, WHO DD and MedDRA and the difference between them?
What is SUSAR?
Adverse Drug Reaction (ADR)
Effectiveness/risk
harm
Essential medicines
Frequency of ADRs
Individual Case Safety Report
ADR Reporting process in PV
VigiFlow
VigiMed
ABBOTTS
COGNIZANT
I 3 GLOBAL DRUG
SAFETY
LAURUS LABS
PARAXEL
SRISTEK
ACCENTURE
CREST.
I GATE PATNI
COMPUTERS
MAHINDRA
SATYAMBSG
PIRAMAL
SUN
PHARMA
ALEMBIC
DIAGNOSEAR
CH
ICON
MAKROCARE
PPD
SYMOGEN
APC PHARMA.
DR REDDY’S
iMEDGlobal,
MANKIND
QUANTUM
SOLUTIONS
SYNOGEN
APCER
ECRON
ACUNOVA
IMS HEALTH
MEDHIMALAYAS
QUINTILES
TAKE
SOLUTIONS
APCER
EMCURE
INC RESEARCH
MEDPACE.
SCIFORMIX
RATIOPHARM
TCS
ASTRAZENECA
FDC
Infocorp
Soft
Solutions
MICRO LABS
RX MD
THOMSON
REUTERS
AUROBINDO
FORTIS
HEALTH CARE
INVENTIVE
MSD (MERCK)
SANTHA
BIOTECH
USV
LIMITED
BESTOCHEM
G7 INFOTECH
IPCA
LABORATORIES
NEKTAR
THERAPEUTICS
SCIFORMIX.
VIMTA LABS
BIOCAD
GENPACT
IPLEX
NORWICH
CLINICAL SERVICES
SHANTHA
BIOTECHNICS
WIPRO
BIOCON
GRANULES
JUBILIANT
BIOSYS NOVARTIS
SIRO
CLINPHARM
WNS
BIOLOGICAL E.
LTD
GVK
KINAPSE
NOVO NORDISK
SP softtech
WOCKHARD
T
BLUEFISH
HCL
LAMBDA
OMNICARECLINICA
L RESEARCH
SRI KRISHNA
PHARMA
4C
Pharma
Solutions
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
If you are marketing your product in India you should comply these area of regulation.We give Services in getting manufacturing licences
ACCREDITED CONSULTANTS PVT.LTD
info@acplgroupindia.co.in
+919310040434
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...Azierta
Farmacovigilancia:
Pharmacovigilance System Master File (PSMF)
Archivo maestro de farmacovigilancia
Good vigilance Practices (GVP)
buenas practicas de farmacovigilancia
Azierta. Consultoría y asesoría científica. Farmacovigilancia España.
TIMELINE
PHARMACOVIGILANCE STAKEHOLDERS
ERMS – RECOMMENDATIONS 2005 – KEY CHANGES
2006 CONSULTATIONS – 2008 PROPOSALS
NEW DIRECTIVE 2010/84/EU
PHARMACOVIGILANCE
New regulation (EC) No 726/2004
PHARMACOVIGILANCE OF HUMAN MPs
PHARMACOVIGILANCE OF VETERINARY MPS
MILESTONES 2011-2012
REGULATION (EU) 520/2012
ICH GUIDELINES
GPvP GUIDELINES
MILESTONES – FURTHER DEVELOPMENT
Introduction
•All medicinal products carry risks in addition to their possible benefits for developing a new medicine, a decision can only be made if both benefits & risks are addressed. Risk associated with the drug is minimized when medicines of good quality, safety & efficacy are used rationally by an informed health professional & by patients. Pharmacovigilance helps in reducing the risk of harm by ensuring use of good quality medicines appropriately. Need of international efforts to address drug safety were realized &
initiated in 1961, following the Thalidomide disaster. Guidelines were developed to monitor drugs, foods & environmental contaminants for adverse reactions & toxicity . In beginning, guidelines were restricted to local needs. Globalization -
recognized need of a system, accepted internationally, to ensure safety
of medicinal products.New drugs: marketed on basis of comparatively limited information, as clinical trials are designed to answer specific questions .•In US, ~ 500 to 2000 patients receive a new drug during clinical trials, & only a few hundred of them are treated > 3-6 months
• In clinical trials, critical efficacy endpoints are identified in advance
& sample sizes are estimated for assessment of effectiveness .
• Common AEs are generally identified & well characterized in
prospective trials
•Infrequent or delayed AE Characteristic depending on their severity
and importance to risk benefits and require special techniques
•Isolated report- definitive in associating a drug with an AE, if drug
administration and event are temporally related, de- challenging or
re-challenging.
•In contrast with few exceptions phase 2 3 trial are not designed to
test specified hypothesis about safety nor to measure identifying AE
with any specified hypotheses about safety nor to measure or identify
AEs with any pre-specified level of sensitivity.
• Exceptions occur when a particular concern related to drug or drug
class has arisen & when there is a specific safety advantage being
studied.
• Safety evaluation during clinical drug development is not expected to
characterize all the AEs, for example, those occurring in < 1 in 1000
patients
•Risks that may be missed include
• rare events
• events occurring after long-term use
• events occurring in special populations
• events occurring in association with specific diseases &
• events occurring in association with concomitant therapy Introduction
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Side effects of drugs products, medical devices & drugs healthcare data...PEPGRA Healthcare
Rapid growth in the use of medical devices in health-care sectors has been enabled by technological advancements. Prescription drugs and medical devices can come with dangerous side effects and complications. A side effect will become severe, so it is essential to contact your doctor or pharmacy specialist if you face ant difficulties. In this blog, Pepgra lists the reporting of side effects and its necessities.
Read More: http://bit.ly/3j0wisP
Contact Us:
Website : https://bit.ly/33Fwsye
Email us: sales.cro@pepgra.com
Whatsapp: +91 9884350006
Visit:www.acriindia.com
ACRI is a leading Clinical data management training Institute in Bangalore India.
ACRI creates a value add for every degree. Our PGDCRCDM course is approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
ACRI is a leading clinical research training Institute in Bangalore India.
ACRI creates a value add for every degree. Our PGDCRCDM course is approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
ACRI is a leading clinical research training institute in Bangalore.
ACRI creates a value add for every degree. Our PGDCRCDM course is approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
IELTS, the International English Language Testing System, is designed to assess the language ability of candidates who need to study or work where English is the language of communication.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
Ethnobotany and Ethnopharmacology:
Ethnobotany in herbal drug evaluation,
Impact of Ethnobotany in traditional medicine,
New development in herbals,
Bio-prospecting tools for drug discovery,
Role of Ethnopharmacology in drug evaluation,
Reverse Pharmacology.
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
The French Revolution Class 9 Study Material pdf free download
Pharmacovigilance overview
1.
2. •What is pharmacovigilance
•Pharmacovigilance center in India
•History of Pharmacovigilance
•Who reports
•What to report
•How it is categorized
•Reporting methods
•Reporting timings
•Flow of data
•Methods to assessment( scales/ algorithms)
•Data mining/ software used
•MedDRA
•Discussion
•conclusion
3. The science and activities relating to the detection,
assessment, understanding and prevention of adverse
effects or any other drug-related problem
a
• Hippocrates’ admonition.
• “First, do no harm”
Humanitarian concerns
Check if drugs on the market fulfill their intended role
in society i.e. if resources spent on drugs produce
optimal results in terms of benefits
Economical concerns
Why pharmacovigilance?
World Health Organisation
4. Drugs withdrawn from Market due to severe ADR
Drug ADR Company Year
Rofecoxib Myocardial infarction Merck 2004
Cerivastatin Rhabdomyolysis Bayer 2001
Cisapride Cardiac arrythmia J&J 2000
Astemizole Cardiac arrythmia J&J 1999
Bromfenac Liver toxicity Wyeth 1998
5. WHO ALL ARE INVOLVED
Regulatory authorities
Animal owner
Veteran
Drug company
Social service personal
Doctor/ dentist/ health professional
Consumer
6. The problem of ADRs
Account for 5% of all hospital admissions.
Occur in 10-20% of hospital inpatients.
Cause death in 0.1% of medical and 0.01% of surgical
inpatients.
Adversely effect patients quality of life.
Cause patients to lose confidence in their doctors.
Increase costs of patients care.
7. What to report: ADVERSE EVENT-1
Any unfavorable, unintended sign, symptom, illness or
experience (untoward medical occurrence) that develops or
worsens in a subject during the period of observation (defined
by protocol) « Adverse event » does not imply causal
relationship with the study medication
• Abnormal results of diagnostic procedures, including
laboratory findings considered by investigator to be of clinical
relevance, are considered to be adverse events
8. ADVERSE DRUG REACTION
“A noxious and unintended
response at doses normally used
for prophylaxis, diagnosis, or
therapy of diseases, or for the
modification of physiological
function.”
All ADRs are AEs…….
but all AEs are NOT ADRs
9. SAE
results in death
is life threatening
requires inpatient hospitalisation or prolongation
of existing hospitalisation
results in persistent or significant
disability/incapacity
is a congenital anomaly/birth defect
is important medical event
10. WHAT IS NOT AN AE/SAE?
Surgical Procedures
They are therapeutic measures of a condition requiring surgery
They are not AEs/SAEs per se;
The condition for which the surgery is performed, may be an AE/SAE which has
to be reported
Surgical procedures planned prior to randomization and conditions leading to
these measures are not adverse events (medical history)
An Unexpected ADR
An ADR whose nature, intensity or incidence falls outside the information
provided in
• the Investigator’s Brochure
• the Package Insert or Product Monograph of a marketed drug
11. Adverse Event
Intensity Seriousness Expectedness
•Mild
•Moderate
• Severe
•Serious
•Non serious
•Expected
•Unexpected
•Related
•Un-related
Relatedness
DIMENSIONS OF AN ADVERSE EVENT
12. OUTCOME OF AN AE & FOLLOW UPS
Complete
recovery
Ongoing
Recovered
with
sequelae
Unknown
Death
13. CAUSAL ASSESSMENT – WHO ALGORITHM
•Certain
•Probable
•Possible
•Unlikely
•Unclassifiable
REPORTING METHOD & SYSTEM
Medwatch
Yellow
Card
ADR
form
14. THE MINIMUM CRITERIA FOR A VALID
ADR REPORT*
Identifiable
patient
A suspect drug
An adverse
event
Identifiable
Reporter
ICH / CIOMS (Centre for international
organization of Medical Science) group V
working recommend
16. LAWS, REGULATIONS AND GUIDELINES
Schedule Y requirements
ICH guidelines
International regulations (US
FDA)
17. 12/17/2015 17
Adv.Event
DCGI
Sponsor
within 14
calendar days
SeriousNon -Serious
Record
in CRF
Record in CRF
SUSAR / U.SAE
Report EXPEDITEDLY
Global Team
HQ
PIs / ECs
DSMB
EC
immediately /
within 24 hours/
within 7 calendar
days
Safety
Review
Safety Profile
Update
18. CURRENT US FDA REGULATIONS
Safety reporting requirements are specified in
Title 21, Code of Federal Regulations:
Part 310.305 Old Drugs (marketed pre-1938)
Part 312.302 Safety reporting from INDs
Part 314.80 Marketed drugs
Part 314.98 Generic drugs
Part 600.80 Therapeutic Biologic products
19. ICH-GCP GUIDELINES - III
E2A Expedited clinical safety reporting
E2B Safety reporting data elements spec’s
E2B(M) Data Elements for Electronic submission
E2C & E2C Addendum – PSURs
E2D Post-marketing expedited reporting standard
E2E Pharmacovigilance planning
20. The post marketing surveillance may comprise of one of
the following;
Phase IV
Clinical
Trials
PMS Studies
Observation
al Studies
Registries
Prescription
Event
Monitoring
Spontaneou
s reporting
21. AIMS OF POST MARKETING SURVEILLANCE
Expose more patients to confirm and better understand safety of new
molecule (delayed effects, prolonged use effects.
Evaluation in unexposed population (children, pregnant women, nursing
mothers, elderly, immuno-suppressed)
Identification of risk groups
Occurrence of rare and serious ADRs
Assessment of costs of ADRs to various sectors of the society
22. SPONTANEOUS REPORT
“An unsolicited communication to a company, regulatory authority or
other organization that describes an adverse drug reaction in a patient
given one or more medicinal products and which does not derive from a
study or any organized data collection scheme is called “Spontaneous
Report”.
Strengths
Cornerstone of ‘PV’
Cheap & Easy
Encompass all clinical settings
Life-time span
Detection of rare ADRs
Weaknesses
Underreporting
Quality of reporting
No denominator
Subject to bias
Delayed effects go undetected
23. Its a formal, structured update of the
worldwide safety experience for a
registered medicinal product (per ICH E2C
standards), prepared for submission to
regulatory authorities at defined times
post-authorization
PSUR- PERIODIC SAFETY UPDATE REPORTS
24. PERIODIC SAFETY UPDATE REPORTS
• New safety information from appropriate sources.
1 • Data to patient exposure.
• Summarizes the market authorization status in different countries.
• Create periodically the opportunity for an overall safety re-
evaluation.
• Indicate whether changes should be made to product information.
25. REPORTING TIMINGS
Schedule Y (Indian) EU Requirements US Requirements
o Only ‘New
Drug’
o Six Monthly –
first 2 years
o Annual –
subsequent 2
years
o To be
submitted
within 30
calendar days
o Even if not
marketed
o Six Monthly – first 2
years
o Annual –
subsequent 2 years
o At the first renewal,
and then
o 5-yearly at renewal
thereafter
o One PSUR for each
active substance
o To be submitted
within 60 days of
last data lock
o Pre-Approval
PSUR – 4
months after
application
o Post Approval
for each
approved
NDA/ANDA/BLA
o Quarterly– for
first 3 years
o Then annual
interval / on
request
o Within 30 days
of the close of
quarter
o Annual reports
within 60 days
27. PV SOFTWARES & DATABASE
1. Intranet / Internet based
2. Restricted Access
3. Level privileges
4. MedDRA / WHO integrated
5. Company Product Library
6. Time bound process
7. QBS
8. Signal generation
9. Report generation
10.Electronic submissions
1. ArgusAERS (US FDA)
2. Eudravigilance
(EMEA)
3. ARIS global
4. Clint race
5. Oracle
28. MedDRA
MedDRA is a clinically-validated international medical terminology
used by regulatory authorities and the regulated
biopharmaceutical industry.
The terminology is used through the entire regulatory process,
from pre-marketing to post-marketing, and for data entry,
retrieval, evaluation, and presentation.”
Med DRA: medical Dictionary for Regulatory Activities
30. MedDRA - Structure
SOC – System Organ class
HLGT – High Level Group Term
HLT – High Level Term
PT – Preferred Term
LLT - Low
Level Term
31. The Gains from PV Database
• Patient’s safety & care
• Dissemination of information to all
concerned
• Regulatory compliance
• Detection of new safety issues
• Changes in design / documents
• Ongoing safety review
• Regulatory actions
32. ADR detection
Subjective report Objective report
patient
complaint
Direct
observation of
event
abnormal
findings
physical exam Laboratory test
Diagnostic
procedure
33. NARANJO's ALGORITHM
Question Yes No Don't
know
Are there previous conclusion reports on this reaction? +1 0 0
Did the adverse event appear after the suspect drug was
administered?
+2 -1 0
Did the AR improve when the drug was discontinued or a
specific antagonist was administered?
+1 0 0
Did the AR reappear when drug was re administered? +2 -1 0
Are there alternate causes [other than the drug] that could
solely have caused the reaction?
-1 +2 0
Did the reaction reappear when a placebo was given? -1 +1 0
34. NARANJO's ALGORITHM
Question Yes No Don’t
know
Was the drug detected in the blood [or other fluids] in a
concentration known to be toxic?
+1 0 0
Was the reaction more severe when the dose was increased,
or less severe when the dose was decreased?
+1 0 0
Did the patient have a similar reaction to the same or similar
drugs in any previous exposure?
+1 0 0
Was the adverse event confirmed by objective evidence? +1 0 0
36. Other methods
Irey’s method
Karch and Lasanga’s Method
Blanc et al’s method
Kramer et al’s method
FDA(Jones Method)
Emmanuel and Sacchetti’s method
The French Method
Stephen’s personal scoring method
Venulet et al’s method
Spanish quantitative imputation scale
37. Methods of assessment
Expert judgment/global
introspection
Algorithms
Probabilistic
methods (Bayesian
approaches)
Three broad categories
38. Methods of assessment
Expert judgments(global introspection):
They are individual assessments based on previous knowledge
and experience in the field.
Algorithms : Are sets of specific questions with associated
scores for calculating the likelihood of a cause-effect
relationship.
Bayesian approaches: use specific findings in a case to transform the
prior estimate of probability into a posterior estimate of probability
of drug causation